3P Biopharmaceuticals and the University of Navarra bring the Neanderthal world and biomedicine to the public in a successful event.
This afternoon Pamplona became the epicentre of knowledge and innovation in the field of biomedicine, thanks to the event "Exploring our shared legacy between Neanderthals and Sapiens: challenges and uncertainties of future biomedicine", organized by 3P Biopharmaceuticals in collaboration with the Faculty of Pharmacy and Nutrition of the University of Navarra.
The event gathered an audience of more than 200 people and was attended by representatives of the Government of Navarra.
This afternoon Pamplona became the epicentre of knowledge and innovation in the field of biomedicine, thanks to the event “Exploring our shared legacy between Neanderthals and Sapiens: challenges and uncertainties of future biomedicine”, organized by 3P Biopharmaceuticals in collaboration with the Faculty of Pharmacy and Nutrition of the University of Navarra. The event attracted a diverse and distinguished audience of more than 200 people, including prominent political representatives of the Government of Navarra.
The event, which took place in the Assembly Hall of the University’s biosanitary Campus, featured a panel of internationally renowned experts in the field of scientific and business research in the healthcare sector. Attendees had the privilege of listening to presentations and discussions moderated by 3P Biopharmaceuticals’ chief commercial officer, Elena Erroba, and which included international experts such as ancient DNA expert Dr. Carles Lalueza Fox; Director of the Science Museum, University of Navarra, Dr. Ignacio Lopez Goñi; Professor at IESE Business School, Dr. Magda Rosenmöller; Vice President, CMC of TrialSpark (3P’s New York-based client), Dr. Silvina García Rubio; and CEO of 3P Biopharmaceuticals, Dámaso Molero.
The event, which explored such exciting topics as the evolution of our species, the relationship between Neanderthals and Sapiens, and the future challenges of biomedicine, allowed the audience to reflect on the vast potential of medical research.
In addition, the presence of prominent local politicians highlighted the importance of the event and its impact on the field of scientific research and innovation in Navarra. Among the dignitaries present were the Minister of Industry and Ecological and Digital Business Transition, Mikel Irujo; the Director General of Science, Technology and Innovation of the Department of University, Innovation and Digital Transformation, Ms. Agurtzane Martínez Ortigosa and from the Directorate General for Business Development of the Government of Navarra, Mr. Iñigo Arruti Torre and Mr. Juan Carlos Artázcoz Sanz.
The success of this event was also reflected in the wide participation of the attendees, who were able to establish contacts and promising collaborations for the future of medical research in Navarra and beyond. The event concluded with the intervention of Mr. Mikel Irujo stating that: “Navarra has a complete ecosystem, universities, reference hospital complexes, technology centres and a business network of more than 80 companies. In short, a value chain that has grown by 23% since 2016, made up of 31,508 professionals, most of them in care services (27,981), although 2,465 people working in the healthcare industry and 1,065 in research.”
3P Biopharmaceuticals and the University of Navarra Faculty of Pharmacy and Nutrition sincerely thank all attendees, speakers, and collaborators for making this event an exceptional achievement. They will continue to work together to drive research and innovation in the field of biomedicine and anticipate future collaborations that will continue to transform the landscape of modern medicine.
About the speakers
Dr. Carles Lalueza Fox is an expert in ancient DNA, director of the Museum of Natural Sciences of Barcelona, researcher at the Institute of Evolutionary Biology (CSIC) and participant in the Neanderthal Genome program.
Dr. Ignacio López Goñi is Professor of Microbiology and Director of the Science Museum, University of Navarra.
Dr. Magda Rosenmöller is a professor at IESE Business School, a member of the Executive Committee of BAHM, an expert advisor on global health issues and policy, and a senior partner at EIT Health.
Dr. Silvina García Rubio is Vice President, Chemistry Manufacturing and Controls at TrialSpark, an American company based in New York also 3P customer.
Dámaso Molero is CEO of 3P Biopharmaceuticals, member of the Board of Directors of ASEBIO (Spanish Association of Biocompanies) and expert member of the “INDUSTRY 2030 High Level Industrial Roundtable”.
